Treatment Challenges in a Patient with Diastolic-Predominant Hypertension and Suspected Antihypertensive Adverse Effects: A Case Report
Year: 2026
Type: article
Study design: Case Report
Abstract: Background and Clinical Significance: Hypertension management can be challenging when suspected adverse drug reactions limit conventional treatment. This case shows how a sequence of treatment changes in a patient with diastolic-predominant office blood pressure elevation and asthma becomes difficult to interpret when out-of-office, rhythm and safety documentation is incomplete. Case Presentation: A 41-year-old man with moderate persistent asthma had office blood pressure averaging approximately 135/95 mmHg and a resting heart rate of 92 bpm, persisting after two months of lifestyle intervention. Ambulatory monitoring was not performed, and home readings were unavailable. Nebivolol, hydrochlorothiazide and perindopril were followed by patient-reported nightmares, somnolence and erectile dysfunction, and nebivolol was stopped. Verapamil was then added, followed by a reported heart rate of 120–130 bpm of undetermined rhythm (no electrocardiogramor rhythm recording), and was stopped. After a limited endocrine evaluation that could not exclude primary aldosteronism, spironolactone and off-label ivabradine (first documented dose 7.5 mg twice daily, the maximum maintenance dose) were added to perindopril and hydrochlorothiazide, with office blood pressure of approximately 120/80 mmHg. Phosphenes occurred, and gynecomastia later prompted a switch to eplerenone; subsequent measurements, biochemistry and outcome were unavailable. Conclusions: The principal problem was treatment tolerability, not confirmed resistant hypertension. The report is a descriptive account of tolerability-driven treatment changes. The missing documentation limits assessment of the indication for escalation, the heart-rate episode, biochemical safety and the final outcome. It does not establish the contribution or necessity of any individual medication, and it should not be read as support for a multidrug strategy or for off-label ivabradine.
Authors: Hristina Zlatanova-Tenisheva, Spas Kitov
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $1,689
OpenAlex ID: W7236560606
